In this study, we are investigating whether standard treatments for recurrent/resistant acute myeloid leukemia (AML) can be tailored to individual patients. Using a new technology called pharmacoscopy (PCY), the effect of various standard therapies on AML cells is tested on a patient blood or bone marrow sample.
Aim of the study
With precision medicine, such as "PCY", it is possible to tailor the choice of therapy to you. With this study, we want to find out whether PCY can improve the choice of therapy.
Who can take part?
Patients with recurrent / resistant acute myeloid leukemia.
Procedure
For you, participation lasts 3 months and ends after the fourth study visit. During the course of your participation, all appointments are part of your general treatment and will be carried out independently of your participation in the study. At the beginning of the study, the investigator decides whether you can take part in the project based on the inclusion and exclusion criteria. We take 30 ml of additional blood and 10 ml of additional bone marrow samples once for the "PCY". Blood and bone marrow samples are routinely collected to assess whether your disease is in remission. After 3 months you will come for a final visit. They will check whether you have received a blood stem cell transplant and whether you have suffered any complications from the therapy.
Compensation
Original study name
Pharmacoscopy-guided clinical standard-of-care in relapsed/refractory acute myeloid leukemia, a randomized phase-2 clinical trial
BASEC number
2023-D0089
Sponsors